Jazz Pharmaceuticals Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy
Jazz Pharmaceuticals plc (Nasdaq: JAZZ)
today presented data from the Phase 2b study evaluating JZP-110 (formerly
known as ADX-N05) as a potential new treatment for the symptoms of excessive
daytime sleepiness (EDS) in adults with narcolepsy. In the study, all primary
and secondary endpoints were met and patients treated with JZP-110 experienced
statistically significant improvements in objective and subjective symptoms of
EDS. Based on these data, Jazz Pharmaceuticals plans to evaluate JZP-110 in
Phase 3 clinical studies in patients with EDS associated with narcolepsy and
in patients with EDS associated with obstructive sleep apnea (OSA), pending
discussions with regulatory agencies.
These data were presented today at a late-breaker session during SLEEP 2014,
the 28th Annual Meeting of the Associated Professional Sleep Societies (APSS),
in Minneapolis, Minn. The annual SLEEP meeting is the premier U.S. conference
for healthcare professionals, advocates and industry partners involved in
"We are committed to developing and commercializing new and differentiated
therapies that address unmet patient needs in sleep medicine, and we believe,
based on the encouraging results from early clinical trials, that JZP-110 has
the potential to significantly help people with narcolepsy and OSA who are
experiencing EDS," said Jeffrey Tobias, M.D., executive vice president,
research and development, and chief medical officer, Jazz Pharmaceuticals.
"As one of the newest additions to our growing sleep clinical development
pipeline, we look forward to advancing the Phase 3 clinical program for this
Click here to see the full press release.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.